Abstract
Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out as a major determinant of efficacy when RT and CDK4/6 inhibitors are combined for breast cancer therapy.
Original language | English |
---|---|
Article number | 1889101 |
Pages (from-to) | 1889101 |
Journal | Oncoimmunology |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - 2021 |
Externally published | Yes |
Keywords
- 4T1 cells
- immune checkpoint inhibitors
- MCF7 cells
- MPA/DMBA-driven mammary carcinomas
- targeted anticancer agents
- TS/A cells
- Cytostatic Agents
- Humans
- Female
- Cyclin-Dependent Kinase 4
- Breast Neoplasms/drug therapy
- Cyclin-Dependent Kinase 6